ASH 2018 | Long-term follow-up of acalabrutinib in CLL
John Byrd
• 1 Dec 2018
In this interview, John Byrd, MD, of Ohio State University, Columbus, OH, discusses the long-term follow-up (44 months) of the ACE-CL-001 trial (NCT02029443), which gave treatment-naïve chronic lymphocytic leukemia (CLL) patients the BTK inhibitor acalabrutinib. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Byrd describes the success of acalabrutinib, with a very large percentage of patients experiencing no disease progression and few suffering from side effects.
